Alliances
With June just getting started, BMS and Sorrento are making new connections. Read on for announcements of these collaborations.
Repare Therapeutics announced a global cancer collaboration valued at up to $1.2 billion with Swiss pharma giant Roche for the development and commercialization of camonsertib.
Eligo Bioscience has thought of a way to solve the dysbiosis between our bodies and our microbiomes – gene editing. BioSpace spoke with Eligo Co-founder and CEOXavier Duportet, Ph.D.
Several new biotech and biopharma companies are sharing their strengths to develop new treatments for high-need diseases diabetes, Alzheimer’s and cancer.
The FDA has issued special designations that could improve the lives of millions with recurrent glioblastoma or hemophilia diagnoses.
The initiative, a partnership between non-profit biotech company n-Lorem and Columbia University, focuses on developing personalized experimental ASO medicines for nano-rare ALS patients.
Germany’s CureVac is partnering with Belgium’s myNEO to identify specific cancer antigens in order to develop novel mRNA immunotherapies for cancer vaccines.
Antios Therapeutics received a clinical hold on its Hepatitis B virus (HBV) combinatorial therapy from the U.S. Food and Drug Administration on Wednesday.
San Francisco-based Terremoto Biosciences launched with $75 million in Series A financing from OrbiMed and Third Rock Ventures as it develops highly targeted, small-molecule medicines.
Two months after closing its Series A financing round, KaliVir Immunotherapeutics forged an exclusive licensing and collaboration agreement with Roche.
PRESS RELEASES